312 related articles for article (PubMed ID: 34129823)
21. TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR.
Wang K; Liu T; Ge N; Liu L; Yuan X; Liu J; Kong F; Wang C; Ren H; Yan K; Hu S; Xu Z; Björkholm M; Fan Y; Zhao S; Liu C; Xu D
Oncotarget; 2014 Dec; 5(23):12428-39. PubMed ID: 25474136
[TBL] [Abstract][Full Text] [Related]
22. Synchronous and metachronous urothelial carcinoma of the upper urinary tract and the bladder: Are they clonally related? A systematic review.
van Doeveren T; van de Werken HJG; van Riet J; Aben KKH; van Leeuwen PJ; Zwarthoff EC; Boormans JL
Urol Oncol; 2020 Jun; 38(6):590-598. PubMed ID: 32057596
[TBL] [Abstract][Full Text] [Related]
23. ANXA10 Expression Is Inversely Associated with Tumor Stage, Grade, and TP53 Expression in Upper and Lower Urothelial Carcinoma.
Kobayashi G; Hayashi T; Sentani K; Ikeda K; Babasaki T; Shigematsu Y; Sekino Y; Uraoka N; Teishima J; Matsubara A; Hinata N; Oue N
Pathobiology; 2023; 90(2):94-103. PubMed ID: 35780773
[TBL] [Abstract][Full Text] [Related]
24. Genomic profile - a possible diagnostic and prognostic marker in upper tract urothelial carcinoma.
Grahn A; Eisfeldt J; Malm C; Foroughi Asl H; Jaremko G; Tham E; Brehmer M
BJU Int; 2022 Jul; 130(1):92-101. PubMed ID: 34375486
[TBL] [Abstract][Full Text] [Related]
25. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update.
Rouprêt M; Babjuk M; Compérat E; Zigeuner R; Sylvester RJ; Burger M; Cowan NC; Böhle A; Van Rhijn BW; Kaasinen E; Palou J; Shariat SF
Eur Urol; 2015 Nov; 68(5):868-79. PubMed ID: 26188393
[TBL] [Abstract][Full Text] [Related]
26. HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC).
Soria F; Moschini M; Haitel A; Wirth GJ; Karam JA; Wood CG; Rouprêt M; Margulis V; Karakiewicz PI; Briganti A; Raman JD; Kammerer-Jacquet SF; Mathieu R; Bensalah K; Lotan Y; Özsoy M; Remzi M; Gust KM; Shariat SF
World J Urol; 2017 Feb; 35(2):251-259. PubMed ID: 27272502
[TBL] [Abstract][Full Text] [Related]
27. Establishment of diagnostic criteria for upper urinary tract urothelial carcinoma based on genome-wide DNA methylation analysis.
Fujimoto M; Arai E; Tsumura K; Yotani T; Yamada Y; Takahashi Y; Maeshima AM; Fujimoto H; Yoshida T; Kanai Y
Epigenetics; 2020 Dec; 15(12):1289-1301. PubMed ID: 32498593
[TBL] [Abstract][Full Text] [Related]
28. Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma.
Simon CT; Skala SL; Weizer AZ; Ambani SN; Chinnaiyan AM; Palapattu G; Hafez K; Magers MJ; Kaffenberger SD; Spratt DE; Montgomery JS; Morgan TM; Udager AM; Lew M; Mehra R
Hum Pathol; 2019 Apr; 86():76-84. PubMed ID: 30537495
[TBL] [Abstract][Full Text] [Related]
29. The clinicopathological characteristics of muscle-invasive bladder recurrence in upper tract urothelial carcinoma.
Shigeta K; Matsumoto K; Ogihara K; Murakami T; Anno T; Umeda K; Izawa M; Baba Y; Sanjo T; Shojo K; Tanaka N; Takeda T; Kosaka T; Mizuno R; Mikami S; Kikuchi E; Oya M
Cancer Sci; 2021 Mar; 112(3):1084-1094. PubMed ID: 33368857
[TBL] [Abstract][Full Text] [Related]
30. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
[TBL] [Abstract][Full Text] [Related]
31. Editorial comment on: FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
Malats N; Real FX
Eur Urol; 2009 Mar; 55(3):658. PubMed ID: 18584942
[No Abstract] [Full Text] [Related]
32. Editorial comment on: FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
Burger M
Eur Urol; 2009 Mar; 55(3):657. PubMed ID: 18584941
[No Abstract] [Full Text] [Related]
33. BUBR1 overexpression predicts disease-specific survival after nephroureterectomy in patients with upper tract urothelial carcinoma.
Yamamoto Y; Oga A; Akao J; Misumi T; Fuji N; Kobayashi K; Kawai Y; Inoue R; Hirata H; Matsumoto H; Nagao K; Sakano S; Matsuyama H
Jpn J Clin Oncol; 2016 Aug; 46(8):754-61. PubMed ID: 27174960
[TBL] [Abstract][Full Text] [Related]
34. Reassessment of p53 immunohistochemistry thresholds in invasive high grade bladder cancer shows a better correlation with TP53 and FGFR3 mutations.
Hodgson A; van Rhijn BWG; Kim SS; Ding C; Saleeb R; Vesprini D; Liu SK; Yousef GM; van der Kwast TH; Xu B; Downes MR
Pathol Res Pract; 2020 Nov; 216(11):153186. PubMed ID: 32861170
[TBL] [Abstract][Full Text] [Related]
35. Consultation on UTUC, Stockholm 2018 aspects of diagnosis of upper tract urothelial carcinoma.
Fojecki G; Magnusson A; Traxer O; Baard J; Osther PJS; Jaremko G; Seitz C; Knoll T; Giusti G; Brehmer M
World J Urol; 2019 Nov; 37(11):2271-2278. PubMed ID: 30915526
[TBL] [Abstract][Full Text] [Related]
36. Investigating cellular similarities and differences between upper tract urothelial carcinoma and bladder urothelial carcinoma using single-cell sequencing.
Zhang Q; Wang C; Qin M; Ye Y; Mo Y; Meng Q; Yang G; Feng G; Lin R; Xian S; Wei J; Chen S; Wang S; Mo Z
Front Immunol; 2024; 15():1298087. PubMed ID: 38903524
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis.
Rizzo A; Mollica V; Santoni M; Massari F
Clin Genitourin Cancer; 2022 Oct; 20(5):482-487. PubMed ID: 35858936
[TBL] [Abstract][Full Text] [Related]
38. FGF7 Over Expression is an Independent Prognosticator in Patients with Urothelial Carcinoma of the Upper Urinary Tract and Bladder.
Fan EW; Li CC; Wu WJ; Huang CN; Li WM; Ke HL; Yeh HC; Wu TF; Liang PI; Ma LJ; Li CF
J Urol; 2015 Jul; 194(1):223-9. PubMed ID: 25623741
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive integrative profiling of upper tract urothelial carcinomas.
Su X; Lu X; Bazai SK; Compérat E; Mouawad R; Yao H; Rouprêt M; Spano JP; Khayat D; Davidson I; Tannir NN; Yan F; Malouf GG
Genome Biol; 2021 Jan; 22(1):7. PubMed ID: 33397444
[TBL] [Abstract][Full Text] [Related]
40. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
van Oers JM; Zwarthoff EC; Rehman I; Azzouzi AR; Cussenot O; Meuth M; Hamdy FC; Catto JW
Eur Urol; 2009 Mar; 55(3):650-7. PubMed ID: 18584939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
